# Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

> **NCT00667251** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 652 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** docetaxel
- **DRUG:** lapatinib ditosylate
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00667251
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-07
- **Primary completion:** 2012-08-01
- **Final completion:** 2022-07-27
- **Target enrollment:** 652 (ACTUAL)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667251, "Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00667251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*